BHI Weekly Newsletter Archives Archives - Page 32 of 65

Apr 02 2019

Love0

348th Edition – April 2, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

April 2, 2019

FOUNDING MEMBER OF

Five Innovative BioHealth Companies Selected to Present Technologies at 4th Annual BioHealth Capital Region Crab Trap Competition

– Winner to be announced during 2019 BioHealth Capital Region Forum –

Five innovative companies focused on the diagnosis or treatment of Multiple Sclerosis, TBI, Autism, Spinal misalignment, and Metastatic Cancer will present their innovative technologies to a panel of judges and industry leaders on April 9th during the 2019 BioHealth Capital Region Forum, at the AstraZeneca campus in Gaithersburg, Maryland. Founded by BioHealth Innovation, Inc. (BHI) and AstraZeneca in 2016, the annual Crab Trap Competition highlights biohealth companies with strong commercial potential. The five finalists were selected from a competitive field of almost fifty entries. The 4th Annual Crab Trap Competition is sponsored by Wilson Sonsini Goodrich & Rosati. The grand prize this year is $10,000.

In 2016, the initial prize was awarded to Sonavex, a commercial stage Johns Hopkins spin-out focused on Empowered Patient Care. The company’s first technology is a dual-component system comprising an FDA-cleared bioabsorbable implant (EchoMark) and an FDA-cleared custom automated ultrasound (EchoSure) to detect post-operative vascular complications prior to catastrophic surgical failures that represent a $3B annual market and cost hospitals up to $577,000 per instance. The company closed a $4.5M Series A in 2018, recently secured a $3M NIH grant and is currently raising its Series B. In 2017, the winner was another Johns Hopkins (JH*) spinout, LifeSprout, developer of a suite of products to address soft tissue needs in the aesthetic and reconstructive markets. Last year’s winner, Galen Robotics, is developing, in partnership with JHU, a surgical robot to make minimally invasive surgeries faster, safer and more precise. The company plans a 510k submission next year, is raising Series A financing, and will be relocating the HQ team in CA to join their engineering experts in Baltimore.

The 2019 BioHealth Capital Region Crab Trap Finalists presenting at the forum at 9:30 a.m. on Tuesday, April 9th, are:

BeCareLink – Predictive Artificial Intelligence Digital Therapeutic Mobile Platform for Multiple Sclerosis and other neurological conditions.

BRAINBox Solutions – Multi-Modality capability to diagnose and provide prognostic information for mild Traumatic Brain Injury.

Floreo Inc. – Leveraging the power of virtual reality to develop a subscription platform that delivers immersive, fun, and affordable lessons for children and adults with autism spectrum disorder (ASD).

Spine Align – Spine Align is a medical device company developing technologies that enable spine surgeons to make real-time intraoperative measurements of spinal alignment.

Unleash Immuno Oncolytics – Developing armed, oncolytic viruses to treat metastatic cancers. Our platform combines tissue-specific control of both viral replication and the expression of human cytokines to provide a dual punch in cancer cells.

Noble Life Sciences’ CEO Srujana Cherukuri, Ph.D. joins Rich Bendis for a New Episode of BioTalk!

A very interesting episode of BioTalk where Srujana Cherukuri, Ph.D. discusses her path from Intern to CEO and where the company is headed next

Before becoming CEO, Dr. Cherukuri served in multiple roles at Noble Life Sciences including Chief Operations Officer, Chief Scientific Officer, Vice President of Product Development and Operations, and Director of Scientific Affairs. In her previous roles at Noble, Dr. Cherukuri was instrumental in optimizing new preclinical animal models and streamlining operations to achieve operational efficiency. In addition, Dr. Cherukuri led the successful consolidation of Noble operations at the Spring Valley Laboratories site. Prior to joining Noble, Dr. Cherukuri held positions at the Cleveland Clinic Foundation, National Cancer Institute and University of Maryland where she led projects focused on understanding the basic biology and mechanistic actions in cancer cells. Dr. Cherukuri has expertise in diverse areas of Biology and has 12+ years of research experience in the areas of oncology and stem cell biology. Dr. Cherukuri completed her PhD in biology at Cleveland State University.

Listen now on iTunes, Google Play, and TuneIn.

Job Opportunity: BHI ASSOCIATE

BioHealth Innovation, Inc. (BHI), is a Montgomery County innovation intermediary which translates market-relevant research into commercial success by bringing together management, funding, and markets. BHI is seeking an early stage life sciences professional to join the BHI team and work within an entrepreneurial environment.

OVERVIEW – BHI ASSOCIATE

Reporting to Senior Analyst, the Associate will assist in the evaluation of early-stage technologies and will provide strategic planning and operational support for start-up companies. The Associate will work directly with BHI EIRs, analysts, and company management in this endeavor. The Associate supports the BHI organization by strategically managing and providing information, intelligence and insights that drive critical business decisions. The Associate will participate in appropriate networking events within the region to represent the BHI mission.

Successful Marketing and PR Strategies for Your Startup

Successful Marketing and PR Strategies for Your Startup

PR and Marketing – What’s the difference?
How do you establish your brand?
Are there tips for marketing on a tight budget?
How do we become known as an Employer of Choice?
How can I become known as a Thought Leader in my field?
How do we get press coverage for our products/service/technology?
What should we budget for our website, social media, PR activities?

SPEAKERS

Sasha Whitaker – American Gene Technologies
Warren Ellis – Montgomery County Economic Dev. Corp.
Jennifer Owers and Rachel Wojnilower – Clark Concepts

SCHEDULE

8:15 a.m. – Networking and Coffee
8:30 a.m. – Discussion with Q&A (in person/by videoconference)
9:45 a.m. – One-on-One Meetings with Experts*

Pre-Registration REQUIRED: RSVP by NOON, 4/3 at tinyurl.com/BHIMktgPR2019

No charge to attend

More Details »

*In person attendance during the discussion is required to participate in 1:1 meeting with experts.

AstraZeneca and Daiichi Sankyo Sign $6.9 Billion Deal for a Single Cancer Drug | BioSpace

AstraZeneca signed a global development and commercialization deal with Daiichi Sankyo for trastuzumab deruxtecan (DS-8201), an antibody-drug conjugate (ADC).

An ADC is a chemotherapy agent attached by a molecular linker to an antibody focused on a specific cancer marker. This way, the antibody delivers the toxic chemical directly to the tumors, minimizing the effects of the chemotherapy on healthy cells.

Innovators – Deadline Extended to April 9th for $250K Pediatric Device Competition

Pediatric orthopedic and spine medical device innovators –good news—the deadline has been extended until Tues., April 9 at midnight EST to apply for the NCC-PDI “Make Your Medical Device Pitch for Kids!” competition with $250K in awards.

This is your chance to capture up to $50,000 in funding and gain access to the first-ever NCC-PDI “Pediatric Device Innovator Accelerator Program” led by MedTech Innovator.

Innovators earning a spot at this one-of-a-kind pediatric accelerator will receive mentorship and support from NCC-PDI’s network of medtech executives, investors, specialty pediatricians and FDA regulatory and business consultants. All finalists will be offered pitch perfect coaching by Entrepreneurs-In-Residence at BioHealth Innovation.

The competition will be held April 30, 2019 at the University of Maryland, College Park. Be part of it!

Jump start your journey to commercialization. The first step is applying here before the April 9, 2019 midnight EST deadline.

BrainScope Completes Large-Scale Clinical Studies of Concussion in Universities, High Schools and Concussion Clinics — BrainScope

BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it had concluded both algorithm development and clinical validation studies in adolescent and young adult populations using its objective, EEG-based technology. The purpose of the studies was to create and validate an objective, personalized capability for assessment of concussion and readiness to return to activities in males and females between the ages of 13-25. The studies conducted from 2015 through 2019 at 52 clinical sites included nearly 1,700 patients and healthy controls, with over 4,000 evaluations. Funding sources for the studies included a $9.9 million research contract from the U.S. Department of Defense, award funding from the NFL-GE Head Health Challenge (in which BrainScope was a two-time awardee), and BrainScope private funding.

Creatv MicroTech’s Liquid Cell Biopsy and CAML cancer biomarker featured at AACR 2019 – Press Release

Creatv MicroTech, detecting and diagnosing cancer when it matters most, will present its latest findings on cancer diagnosis and treatment at the Annual American Association for Cancer Research (AACR) Meeting at Atlanta, Georgia, March 29 – April 3, 2019. Two posters will showcase the clinical utility of cancer-associated macrophage-like cells (CAMLs) biomarker.

Abstract No. 437 / 9: “Combining circulating stromal cells with cell free DNA for increased sensitivity in profiling oncogenic mutations and indicates highly aggressive non-small-cell lung cancer,” investigating the clinical potential of Circulogene’s Patient Mutation Load (PML) analysis from matched cfDNA, CAMLs, and tumor tissue to evaluate progression free survival (PFS) and overall survival (OS) in non-small-cell lung cancer (NSCLC).

Dr. Kurt Newman @ Children’s National Health System – Innovations in Pediatrics by The #PopHealth Show

Join us today as we speak with Dr. Kurt Newman from Children’s National Health System about innovations in pediatrics.

LRIG Metro DC Spring Show

April 4, 2019 3pm-6:30pmUniv. Shady Grove Convention Center 9630 Gudelsky Drive, Rockville, Maryland 20850

Welcome to the Spring 2019 Meeting of the Metro DC Chapter of the Laboratory Research Interest Group! Although we have deep roots in Laboratory Automation, we also invite you to learn about other research technologies, new tools, and projects that are available and ongoing in the Capitol Bioscience hub!

This years theme is Emerging Technologies at the Forefront of Bioscience, with emphasis on 3D Cell Printing, Organoids, Tissue-On-Chip models, and Artificial Intelligence in Bioscience.

Attendance is free with your Eventbrite reservation, and we encourage you to register early.

AstraZeneca to support creation of Life Sciences Innovation Park in China

AstraZeneca is spearheading the creation of a new life sciences park, in Wuxi, China, that aims to nurture innovation by bringing together local and international companies, government, and medical and academic institutions to help create a world-class healthcare innovation ecosystem.

Initial Results from Autolus Therapeutics’ ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting | Autolus Therapeutics plc

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that Claire Roddie MB, PhD, FRCPath, honorary senior lecturer, Cancer Institute, University College London (UCL), presented today initial data from the ongoing Phase 1/2 ALLCAR19 trial of AUTO1 in adult acute lymphoblastic B cell leukemia (ALL) as a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia.

FDA CBER director Peter Marks on developing rare disease gene therapies – Business Insider

These are boom times for gene therapy, an innovative type of medicine that works to treat disease at the genetic level to offer a longer-lasting treatment and potentially even a cure.

Useful Stats: Sources of funds for R&D at colleges and universities, by state | SSTI

Outside of the private sector, colleges and universities perform the vast majority of R&D in the United States – but where do these funds come from? An SSTI analysis of data from the National Science Foundation’s National Center for Science and Engineering Statistics (NSF NCSES) finds that, across the country, the federal government was the source of more than half (53.5 percent) of all R&D performed at colleges and universities in 2017. Institutional funds (25.1 percent), nonprofit organizations (6.8 percent), businesses (5.9 percent), state and local governments (5.6 percent), and other sources (3.0 percent) comprised the remaining sources of higher education R&D funding. The interactive chart below shows the breakdown of funding sources for research and development at colleges and universities for each state.

The Region’s Leaders are Talking About the Capital CoLAB

Last week, the Greater Washington Partnership (the Partnership) and Business Roundtable (BRT) held an event showcasing the Capital CoLAB (Collaborative of Leaders in Academia and Business). The Capital CoLAB is an action-oriented partnership of university and business leaders across the Capital Region, from Baltimore to Richmond, who have come together to position the region as a leading global hub for innovation.

Thermo Fisher to buy gene therapy contract manufacturer Brammer Bio for $1.7B – MedCity News

A company that makes products for science researchers has bought one of the largest contract manufacturers of viral vectors for gene therapy.

2019 NCI and FNL Technology Showcase – Keynote Speaker: BHI’s Rich Bendis

We are excited to announce that Rich Bendis of BioHealth Innovation will be the keynote speaker at the 2019 Technology Showcase. Now in its third year, the Technology Showcase promises to be a “must attend” event for biotech stakeholders in Maryland/DC/VA region. Check out the event page to learn more about our keynote speaker and some of the great panel sessions that we have planned.

Make sure to reserve time on your calendar for the afternoon of Wednesday, June 12.

The 2019 Technology Showcase is a half-day event that will showcase technologies being developed at the NCI and the Frederick National Laboratory for Cancer Research (FNLCR) to encourage startup company formation, technology licensing and collaborations. Innovators, entrepreneurs, investors and business development professionals should attend.

Apr 02 2019

Love0

347th Edition – March 26, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

March 26, 2019

FOUNDING MEMBER OF

MedImmune spinout Viela Bio raising another $75M – Washington Business Journal

Viela Bio had raised $282 million when it launched at the end of February 2018.

Interview: Viela Bio Eyes BLA for Lead Asset Only One Year After Launch | BioSpace

One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration (FDA) for its lead asset, inebilizumab.

2019 Fifth Annual BioHealth Capital Region Forum – Only 2 Weeks Left to Register

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Maryland Tech Council, University System of Maryland, Children’s National Health Network, HemoShear, GSK, BeneVir, Quality Biological, Johns Hopkins University and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

REGISTER TODAY!

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax | Vaccines | News Channels

Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) following a two-dose schedule administered intramuscularly in healthy adults. AV7909 is being developed for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure.

Join us April 4, 2019 – PATHFINDER INNOVATION PROGRAM

Successful Marketing and PR Strategies for Your Startup

PR and Marketing – What’s the difference?
How do you establish your brand?
Are there tips for marketing on a tight budget?
What should an effective marketing plan include?
How can a strong digital strategy build credibility?
How do I get press coverage for my product/service/technology?
What type of budget is realistic for marketing/public relations activities?

SPEAKERS

Sasha Whitaker – American Gene Technologies
Warren Ellis – Montgomery County Economic Dev. Corp.
Jennifer Owers and Rachel Wojnilower – Clark Concepts

SCHEDULE

8:15 a.m. – Networking and Coffee
8:30 a.m. – Discussion with Q&A (in person/by videoconference)
9:45 a.m. – One-on-One Meetings with Experts*

Pre-Registration REQUIRED: RSVP by NOON, 4/3 at BHI@BioHealthInnovation.org

No charge to attend

More Details »

*In person attendance during the discussion is required to participate in 1:1 meeting with experts.

Altimmune Announces Positive Results from NasoVAX Extension Study

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate. Data from this study demonstrated that 100% of the evaluated subjects remained seroprotected, and the seroconversion rate was unchanged more than one year after vaccination.

2019 NCI and FNL Technology Showcase – Keynote Speaker: BHI’s Rich Bendis

Make sure to reserve time on your calendar for the afternoon of Wednesday, June 12.

Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing – Paragon Bioservices, Inc.

Paragon Bioservices, the leading private equity-backed, biologics contract development and manufacturing organization (CDMO) announced today the appointment of Thomas VanCott, Ph.D., as Chief Technology and Strategy Officer (CTSO), along with several key promotions and new hires.

Johns Hopkins spinout Vixiar gets $1.5M for tablet-based cardiac measurement system | MobiHealthNews

Vixiar, a Johns Hopkins spinout marketing a tablet-based point of care system for assessing cardiac filling pressure, has raised $1.5 million in Series A funding. This brings the company’s total funding to $3 million.

GSK pancreatic cancer drug heads to phase 1 combo with Merck’s Keytruda after positive mouse trial | FierceBiotech

GlaxoSmithKline’s experimental drug GSK095 is designed to work in tandem with checkpoint inhibiting medicines in the hopes of empowering the immune system to launch a more aggressive attack against tumors than it does with checkpoint inhibitors alone. Early results from a preclinical trial of a related GSK drug suggest that the combo holds promise in treating pancreatic cancer—so much so that the company is launching a phase 1 study of the drug in combination with Merck’s blockbuster PD1 checkpoint inhibitor Keytruda.

Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases

HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced an extension of its partnership with Takeda Pharmaceutical Company Limited to discover and develop additional novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH).

Researchers at Johns Hopkins offer new protocol to potentially cure sickle cell disease

There’s new hope for patients who have blood diseases. Johns Hopkins Kimmel Cancer Center researchers say a new protocol offers the possibility of a cure. One patient who tried the treatment says it didn’t just change her life, it saved it.

What’s behind sky-high valuations of biopharma startups? – MedCity News

2018 was undoubtedly one of the most important years ever for biopharma, setting records for valuations and dealmaking. But a paper published in January called some of that exuberance into question, noting that many startups over the years have managed to become unicorns – with valuations of $1 billion or more – despite having little or no published, peer-reviewed data.

Top 10 Immuno-Oncology Collaborations

A sampling of recent reports shows just how much immuno-oncology continues to grow. Last month, GrandView Research projected a more than doubling of the global cancer immunotherapy market, from the $58.1 billion it tallied in 2018, to $126.9 billion by 2026. As GEN noted when it ranked the top immuno-oncology startups in February, market projections range from $124.88 billion (Transparency Market Research) to $173 billion (Market Research Engine) by 2024.

How Do You Start A Biotech Company?

To launch a company that might attract the investment you need to develop a promising new drug candidate or research tool you need to assemble at least two, but preferably all, of these three things: (a) intellectual property (IP), (b) proof of principle, and (c) team with some biotech experience.

Flagship Pioneering raises $824M in new fund – MedCity News

A life sciences-focused venture capital firm has raised more than $800 million for its latest fund.

Mar 19 2019

Love0

346th Edition – March 19, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

March 19, 2019

FOUNDING MEMBER OF

Anne Lindblad, Ph.D., President, and CEO of Emmes, joins Rich Bendis for BioTalk

BioTalk Host Rich Bendis sits down with Anne Lindblad, Ph.D., President, and CEO of Emmes, to discuss her view of the region, her history with the company, and their mission, vision, and values.

Anne Lindblad, Ph.D., joined Emmes in 1982 as a Biostatistician and is currently the President and CEO. She has supported clinical research throughout her career, serving as Principal Investigator of projects spanning diverse disease areas, including neurology, ophthalmology, oncology, dialysis, transplantation, speech and hearing, and dentistry. Dr. Lindblad has been an NIH reviewer on multiple project applications for NINDS, NEI, NICHD, NIDCR, NIDDK, and NCCAM and has served as a member or chair of several Data and Safety Monitoring Committees for NEI, NIAAA, NIDDK, and NINDS. She was a member of an Advisory Committee charged with drafting policy to shape the appropriate planning and conduct of intramural studies at NIH. She was elected to the Board of Directors for the Society for Clinical Trials (2003-2006) and served as Program Chair (2002), as an Officer (2006-2014), and as President (2012-2013). Dr. Lindblad was selected to serve on NIH’s National Advisory Dental and Craniofacial Research Council from 2004 through 2008. She has taught courses in best practices in clinical trial design and conduct for ophthalmologists, neurologists, and immunologists. She has published and presented over 100 manuscripts in peer-reviewed journals and conferences. Dr. Lindblad joined the Board of BioHealth Innovation in 2018. Emmes has grown from 15 employees in 1982 to over 650 globally. In 2019 Emmes announced a significant investment by Behrman Capital which will allow Emmes to gain access to new tools, talent, service offerings, and expanded footprint faster than what Emmes might otherwise have accomplished.

Listen now on iTunes, Google Play, and TuneIn.

2019 Fifth Annual BioHealth Capital Region Forum…Great Speakers and Networking…Register Today!

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

REGISTER TODAY!

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Osiris to be acquired by British medical device company for $660.5M – Baltimore Business Journal

Columbia-based Osiris is coming off a tumultuous three-year period in which four CEOs left the company and several former executives faced criminal charges for fraud.

We’re not doing enough for our kids | Kurt Newman | TEDxTysons – YouTube

It all begins at birth. That’s the starting point for Kurt Newman as he shares his poignant journey as a pediatric surgeon. Newman offers a new perspective for approaching the most chronic and debilitating health conditions. Against a backdrop of personal challenges and patients who overcame impossible odds, we learn to appreciate the importance of treating every child with early customized care, and an eye for the future.

Built For Bio: Greg Merril, CEO of Adaptive Phage Therapeutics — MCEDC

MCEDC discovers how Greg’s clinical-stage company in Montgomery County, MD is using bacteria phage to combat the worldwide crisis in multi-drug resistant bacterial infections.

New Study Shows Bayh-Dole is Working as Intended

Just as the drug pricing debate on Capitol Hill is heating up, an important new study, “The Bayh-Dole Act’s Vital Importance to the U.S. Life-Sciences Innovation System,” published by the Information Technology & Innovation Foundation (ITIF), underscores the law’s contribution to the United States’ lead in the life sciences. The report warns that attempts to misuse the march-in rights provision of the law to control drug prices would have serious consequences to our competitiveness and our health.

Successful Marketing & PR Strategies for Your Startup (4/4)

PR and Marketing – What’s the difference?
How do you establish your brand?
Are their tips for marketing on a tight budget?
What should an effective marketing plan include?
How can a strong digital strategy build credibility?
How can I get press coverage for my product/service/technology?
What type of budget is realistic for marketing/public relations activities?

Learn the answers to these questions and more through the April 4th PathFinder Innovation Program. (There is no charge to attend in person or by videoconference, however, pre-registration by NOON, 4/2 is required).

8:15 a.m. Networking and Coffee8:30 a.m. – Issues Overview and Discussion (in person/by videoconference)

Pam Clark, Principal, Creative Director – Clark Concepts
Warren Ellis, VP of Marketing, Montgomery County Economic Development Corp.
Rachel Wojnilower, Digital Marketing Manager – Clark Concepts
Jennifer Owers, WebDesigner/Project Manager – Clark Concepts

9:45 a.m. – 1:1 Office Hours (in person/by videoconference)*

This program is cosponsored by BioHealth Innovation, Launch Workplaces, and TEDCO. It is open to anyone in the BioHealth Capital Region.

To register/for more information, email: BHI@BioHealthInnovation. (Please include in your RSVP: Your company name, your title and contact information, the type of product(s) services you are promoting, and your interest in a 1:1 meeting following the overview session.)

*Attendance at Overview in person/by videoconference is required to participate in 1:1 sessions.

BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time · BioBuzz

In 1942, Austrian economist Joseph Schumpeter wrote, “ …industrial mutation—if I may use that biological term—that incessantly revolutionizes the economic structure from within, incessantly destroying the old one, incessantly creating a new one. This process of Creative Destruction is the essential fact about capitalism.”

The Universities at Shady Grove April 6 Expo Targets Potential Undergraduates | Montgomery Community Media

The Universities at Shady Grove (USG) will hold a Undergraduate Expo Saturday, Apr. 6 from 9 a.m. to noon. USG is part of the University System of Maryland and offers approximately 80 undergraduate and graduate degree programs from nine different state universities on the Rockville campus.

Alexandria Real Estate Equities, Inc. Announces Pricing of Public Offering of $200,000,000 of Senior Notes due 2024, $350,000,000 of Senior Notes due 2026 and $300,000,000 of Senior Notes due 2049

Alexandria Real Estate Equities, Inc. (“Alexandria” or the “Company”) (NYSE: ARE) today announced that it has priced a public offering of $200,000,000 aggregate principal amount of 4.000% senior notes due 2024, $350,000,000 aggregate principal amount of 3.800% senior notes due 2026 and $300,000,000 aggregate principal amount of 4.850% senior notes due 2049. Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC and SMBC Nikko Securities America, Inc. are acting as joint book-running managers in connection with the public offering and Barclays Capital Inc., BB&T Capital Markets, a division of BB&T Securities, LLC, BBVA Securities Inc., BNP Paribas Securities Corp., Capital One Securities, Inc., Evercore Group L.L.C., Fifth Third Securities, Inc., Mizuho Securities USA LLC, PNC Capital Markets LLC, RBC Capital Markets, LLC, Regions Securities LLC, Samuel A. Ramirez & Company, Inc., Scotia Capital (USA) Inc., SunTrust Robinson Humphrey, Inc., TD Securities (USA) LLC, U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC are acting as co‑managers in connection with the public offering.

Personal Genome Diagnostics CE Marks Liquid Biopsy Test | BioSpace

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced that it has applied the CE mark to PGDx elio™ plasma resolve. It is the first kitted plasma-based NGS oncology test to have that certification, enabling greater access to genomic testing for cancer patients in Europe.

Sonavex readies to launch sales of medical tech with new FDA clearance – Baltimore Business Journal

Sonavex is first targeting the reconstructive surgery market with its new medical technology, which just earned its final FDA clearance.

LifeBridge Health and CareFirst are hosting an ‘innovation challenge’ for digital health startups – Technical.ly Baltimore

A pair of Baltimore healthcare leaders are partnering to reach digital health startups.

Hospital network LifeBridge Health and health insurance provider CareFirst BlueCross Blue Shield will be hosting an innovation challenge that includes a chance to pitch and win funding for companies.

Biopharma breathes ‘sigh of relief’ with HHS’ interim FDA appointment: analyst | FiercePharma

It didn’t take long for the Trump administration to tap Ned Sharpless, now director of the National Cancer Institute, to take the reins at FDA for now—or for biopharma to hail the news. In fact, one team of analysts said the industry would “breathe a collective sigh of relief.”

How Eargo Is Destigmatizing Hearing Loss Through Innovation

Eargo, a direct-to-consumer health technology company that is destigmatizing hearing loss through innovation, announced it raised $52 million in Series D funding from existing investors New Enterprise Associates (NEA), the Charles and Helen Schwab Foundation, Nan Fung Life Sciences, and Maveron. And new investor Future Fund also participated in this round.

Amazon’s joint health-care venture finally has a name: Haven

The joint health-care venture between Amazon AMZN , J.P. Morgan JPM and Berkshire Hathaway BRK.A finally has a name: “Haven.”

Top 15 Best-Selling Drugs of 2018

For American patients aching for relief from the sky-high price of drugs, the news has been decidedly mixed recently.

Study: Memories of music cannot be lost to Alzheimer’s and dementia

The part of your brain responsible for ASMR catalogs music, and appears to be a stronghold against Alzheimer’s and dementia.

Houston scientist wins Nobel Prize for breakthrough cancer treatment – CultureMap Houston

The already much-heralded University of Texas MD Anderson Cancer Center has just scored global bragging rights. James Allison, Ph.D., a scientist at MD Anderson Cancer Center, has been awarded the 2018 Nobel Prize in Physiology or Medicine, it was announced on October 1.

Mar 18 2019

Love0

345th Edition – March 12, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

March 18, 2019

FOUNDING MEMBER OF

FOURTH ANNUAL CRAB TRAP COMPETITION – Final Week to Apply

YOU THOUGHT SHARK TANK WAS TOUGH?

APPLY NOW!

Submit your application for a chance to be named the Startup with the Most Commercial Potential at the BioHealth Capital Region Forum, win $10,000 and more!

APPLICATION DEADLINE: March 15, 2019

FINALISTS ANNOUNCED: March 21, 2019

PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Distinguished Judges:

Moderator – Rich Bendis, President and CEO, BioHealth Innovation

2019 Judges

John Rubin, Executive Director, JP Morgan Private Bank
Charles J. Andres, Intellectual Property Associate, Wilson Sonsini Goodrich & Rosati (WSGR)
Raghav Bhargava, Associate, New Enterprise Associates (NEA)
Ethel Rubin, Entrepreneur in Residence, NIH
Shaun Grady, Vice-President Business Development Operations, AstraZeneca
Norm Marcus, MD, Venture Partner, Sanderling Ventures

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of attendees and prominent industry and venture capital judges

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

PAST WINNERS: Sonavex (2016) LifeSprout (2017) Galen Robotics (2018)

2019 BioHealth Capital Region Forum – Registration Open

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

Register at bhcrf2019.eventbrite.com

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Behrman Capital Makes Significant Investment in Emmes

Emmes today announced that Behrman Capital, a leading private equity firm, has made a significant investment in the company. The capital will allow Emmes, one of the Washington area’s top 100 largest private companies, to expand and strengthen its service offerings and international presence.

Sonavex Receives FDA 510(k) Clearance for EchoSure

Sonavex, Inc., a privately held medical device company focused on empowered patient care, announced today that on March 8, 2019 it received 510(k) clearance from the U.S. Food and Drug Administration for its EchoSure device to deliver definitive blood flow data on demand.

Successful Marketing & PR Strategies for Your Startup (4/4)

PR and Marketing – What’s the difference?
How do you establish your brand?
Are their tips for marketing on a tight budget?
What should an effective marketing plan include?
How can a strong digital strategy build credibility?
How can I get press coverage for my product/service/technology?
What type of budget is realistic for marketing/public relations activities?

8:15 a.m. Networking and Coffee8:30 a.m. – Issues Overview and Discussion (in person/by videoconference)

Pam Clark, Principal, Creative Director – Clark Concepts
Warren Ellis, VP of Marketing, Montgomery County Economic Development Corp.
Rachel Wojnilower, Digital Marketing Manager – Clark Concepts
Jennifer Owers, WebDesigner/Project Manager – Clark Concepts

9:45 a.m. – 1:1 Office Hours (in person/by videoconference)*

This program is cosponsored by BioHealth Innovation, Launch Workplaces, and TEDCO. It is open to anyone in the BioHealth Capital Region.

*Attendance at Overview in person/by videoconference is required to participate in 1:1 sessions.

BHI Entrepreneur-in-Residence Feedback Session – March 20th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up by noon 3/19 to schedule your feedback session with BHI Entrepreneurs-in-Residence (who have industry experience in therapeutics, Dx, medtech and more) next Wednesday, March 20th. (The next session is scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here(“EIR resource” at BHI). For questions/more information, contact BHI.

TEDCO Generates $1.6 Billion in Economic Benefits to the State of Maryland and Supports 7,746 Maryland Jobs, According to New Independent Study | TEDCO

The Maryland Technology Development Corporation (TEDCO), Maryland’s economic engine for technology companies, announced today the findings of an independent economic impact study detailing the economic development contributions of TEDCO’s five core programs to the state of Maryland.

Hopkins professors receive grants to commercialize research – Maryland Daily Record

Four Johns Hopkins professors received grants through a fund created to help faculty put their research on a path to commercialization.

The professors received grants between $25,000 and $100,000 from the Bisciotti Foundation Translational Fund.

UM BioPark Driving Growth in Maryland Economy – University of Maryland, Baltimore

UMB has long been one of the state’s most powerful economic drivers, stimulating $3 billion in economic activity in 2018, up from $2.8 billion in 2016. A significant factor in that growth is the UM BioPark, which occupies 14 acres in West Baltimore providing laboratory and office space to 41 biotechnology companies and over 1,000 employees.

Pediatric orthopedic & spine device accelerator program accepting pitches — 5 things to know

The National Capital Consortium for Pediatric Device Innovation is accepting applications for its Make Your Medical Device Pitch for Kids competition.

These 3 tech investors are the most active in the DMV: report – Technical.ly DC

Three investment firms topped the list of local tech investors in the DMV region according to CB Insights‘ report, The United States of Venture Capital.

Chinese-born legislator makes history in US local politics

One woman is making her mark at the highest level of U.S. local politics.

She was born in China and successfully carved her path all the way to the state capitol.

CGTN’s Frances Kuo has her story.

Counties Support Kirwan “Blueprint” Bill as Worthy First Steps – Conduit Street

On Wednesday, MACo Legislative Committee members Craig Rice (Montgomery), Jan Gardner (Frederick), and Laura Price (Talbot) joined Executive Director Michael Sanderson in support of SB 1030 The Blueprint for Maryland’s Future.

Navigating the Challenges of Cell-Based Immunotherapies

Cell therapy is emerging, cell by cell, into the repertoire of medical therapies. However, it still has not broken into mainstream use. For instance, there are only two FDA-approved chimeric antigen receptor (CAR) T-cell treatments in the United States: Kymirah, Novartis’s treatment for acute lymphoblastic leukemia, and Yescarta, Kite Pharma’s treatment for non-Hodgkin’s lymphoma.

Rare disease racers speak out, stand tall at Racefor7 events in the U.S. and India

Visibility, speaking out, courage and organization. Forty years ago, these were the things that brought the Orphan Drug Act to life. On Sunday, February 24, across the U.S. and India, over 7,000 supporters gathered in the same passion: speaking out and bringing visibility to the more than 7,000 disorders collectively known as rare diseases, organized under the banner of Racefor7USA and its parent organizations, the Organization for Rare Disease India (ORDI) and Organization for Rare Diseases India in the U.S. (ORDIUSA).

Be Bold. Cutting-edge Lab Space Available at the Gateway of the NIH. Delivering Summer 2021.

Cutting Edge Lab Space Available

The NIH is the cornerstone to the world scientific community and is the largest life sciences engine in the US.

Bethesda Bio gives life science companies the ability to be on the doorstep of this invaluable wealth of resources, community, talent, technology, intellectual property, clinical studies. The existing Bethesda central business district provides a vibrant live, work and play environment to recruit and retain the best scientific minds. Over the past two decades, Bethesda has been the center of Montgomery County and the hub of innovation.

London HIV patient becomes second worldwide in remission, giving hope – Business Insider

An HIV-positive man in Britain has become the second known adult worldwide to be cleared of the AIDS virus after he received a bone marrow transplant from an HIV resistant donor, his doctors said.

Mar 18 2019

Love0

344th Edition – March 5, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

March 18, 2019

FOUNDING MEMBER OF

FOURTH ANNUAL CRAB TRAP COMPETITION – Only 2 Weeks Left to Register

YOU THOUGHT SHARK TANK WAS TOUGH?

APPLY NOW!

Submit your application for a chance to be named the Startup with the Most Commercial Potential at the BioHealth Capital Region Forum, win $10,000 and more!

APPLICATION DEADLINE: March 15, 2019

FINALISTS ANNOUNCED: March 21, 2019

PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Distinguished Judges:

Moderator – Rich Bendis, President and CEO, BioHealth Innovation

2019 Judges

John Rubin, Executive Director, JP Morgan Private Bank
Charles J. Andres, Intellectual Property Associate, Wilson Sonsini Goodrich & Rosati (WSGR)
Raghav Bhargava, Associate, New Enterprise Associates (NEA)
Ethel Rubin, Entrepreneur in Residence, NIH
Shaun Grady, Vice-President Business Development Operations, AstraZeneca
Norm Marcus, MD, Venture Partner, Sanderling Ventures

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of attendees and prominent industry and venture capital judges

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

2019 BioHealth Capital Region Forum – Registration Open

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

Register at bhcrf2019.eventbrite.com

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Strong interest in Non-Dilutive Funding Programs

More than 120 people registered for last week’s SBIR Workshop at IBBR organized by BioHealth Innovation in partnership with Launch Workplaces and support from TEDCO and NIH FCU.

The event featured program overviews, “how to” sessions regarding specific aspects of proposal development and 1:1 partnering meetings with the program managers.

Speakers included: Todd Haim, Ph.D., Chief, Office of Small Business Research NIA; Mike Pieck, Ph.D., Small Business Coordinator, NHLBI; Maureen (Cusick) Thomas, Outreach Coordinator, NIA;Victor Prikhodko, Business Advisor, NIDA; Amir Rahbar, PhD, MBA, Program Director, NCI; Vladimir M. Popov, PhD, Business Dev. Manager, NCI-FNL;Amir Rahbar, PhD, MBA, Program Director, NCI; Henry Ahn, Program Director SBIR/STTR, NSF; and Colleen Gibney, SBIR Deputy Project Mgr, USAMRMC.

44% of the attendees had applied for SBIR funding before with half of these innovators receiving a Phase 1. Only 16% had received a Phase II award. The majority of attendees were from Montgomery and Frederick Counties and the City of Baltimore. However, registrants also traveled from Virginia, DC, Illinois and Pennsylvania.

BioHealth Innovation Entrepreneur-in-Residence Feedback – March 20th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up by noon 3/19 to schedule your feedback session with BHI Entrepreneurs-in-Residence, who have industry experience in therapeutics, Dx, medtech and more March 20th. (Future session scheduled for 5/22.) Pre-registration is required; sign up here (“EIR resource” at BHI). For questions/more information, contact BHI.

MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company

MaxCyte, the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement. Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation® Technology to enable non-viral cell engineering for development of multiple CAR-T drug candidates for up to 10 targets.

NexImmune raising $10M for AML drug trials – Washington Business Journal

The company has already raised about $40 million to date.

State Department awards Emergent BioSolutions contract for chemical warfare countermeasures – Homeland Preparedness News

Emergent BioSolutions announced today that the company has signed a deal with the U.S. Department of State to establish a supply chain for certain medical countermeasures that address chemical warfare agents.

NCC-PDI Announces $250K Pediatric Pitch Competition for Orthopedic Medical Device Innovators

The National Capital Consortium for Pediatric Device Innovation (NCC-PDI) is now accepting applications for its “Make Your Medical Device Pitch for Kids!” competition. The competition is focused on pediatric devices developed for use in the orthopedic and spine sector, an area of critical need which lacks innovation. Winning companies receive awards up to $50,000 and are invited to participate in the newly created NCC-PDI “Pediatric Device Innovator Accelerator Program” led by MedTech Innovator.

Gilead’s Kite pens 10-target CAR-T tech deal with MaxCyte – FierceBiotech

Gilead’s Kite Pharma has expanded its CAR-T agreement with MaxCyte. The revised deal gives Kite the chance to apply MaxCyte’s transfection technology to up to 10 targets.

Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors :: Rexahn Pharmaceuticals, Inc. (RNN)

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced the appointment of Lara S. Sullivan, M.D. to its board of directors.

Personal Genome Diagnostics Welcomes New Members to Board of Directors, Bringing Proven, Industry-Leading Experience in Precision Medicine and Healthcare Policy

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, announced today that it has added two new members to its Board of Directors, Dr. Kavita Patel and Garry Allen Nicholson. Dr. Patel and Mr. Nicholson bring significant healthcare expertise that is aligned with and can further empower PGDx’s corporate growth strategy of driving global access to precision medicine in oncology.

Local Entrepreneur Brings Swedish Company AcouSort to BioHealth Capital Region · BioBuzz

For every AstraZeneca, there are hundreds of small biotech startups and scores of life science innovators that are critical to growing the BioHealth Capital Region. For every new biotech flush with investment cash, scores of smart, entrepreneur-scientists with great ideas and technology struggle to find regional funding partners.

BioFactura CEO Dr. Darryl Sampey Shares his Entrepreneurial Journey at Frederick’s StartupGrind Event – BioBuzz

Dr. Darryl Sampey has been through the grind as CEO of Frederick’s BioFactura, a thriving biotech company that’s a key part of the BioHealth Capital Region’s second largest biotech hub. On a rainy, cold February night at FITCI, Sampey shared BioFactura’s compelling story during a “fireside chat” hosted by StartUp Grind’s Frederick chapter.

BioBuzz with JHU MoCo – March 13th

When: Wednesday, March 13, 2019 from 5:00 PM to 7:00 PM

Where: Bar Louie 150 Gibbs St Rockville, MD 20850

Join BioBuzz and Founding Sponsor JHU MoCo for our next exciting event of 2019 at Bar Louie in Rockville on March 13th.

The Johns Hopkins University Krieger School of Arts and Sciences created the Center for Biotechnology Education to engage diverse audiences in the world of biotechnology and to prepare the leaders of today, tomorrow and the next generation for the challenges of the 21st century.

New ebook: How Protenus fast-tracked hiring with a more focused strategy – Technical.ly Baltimore

In late 2017, Baltimore-based healthcare startup Protenus was reverberating from a year of growth.

Her biotech firm solves medical mysteries. (And no, it’s not Theranos.)

I was dubious when Crystal Icenhour approached me to write about her medical testing company.

New study finds $9 billion in technology sales following NCI-funded research | TechLink

The National Cancer Institute’s investment in small business research grants has supported strong economic growth, including $9 billion in sales of new technologies.

Want to raise $75M in funding? NEA investor explains how Baltimore’s PGDx did it – Baltimore Business Journal

Justin Klein, as a former investor with NEA, helped lead PGDx’s $21.4 million Series A in 2015 and its $75 million Series B last year.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn’t Died – RealMoney

The biotech sector has been a strong performer in 2019 after becoming quite oversold during the plunge in the high-beta parts of the market in the fourth quarter of 2018. Helping the sector recover and get off to a raucous start to the New Year were large buyouts of Celgene Corp(CELG) and Loxo Oncology Inc(LOXO) to start 2019, both with significan…

NEA is raising its biggest fund ever – – again – TechCrunch

New Enterprise Associates, the 41-year-old venture firm with offices in Menlo Park; San Francisco; Boston; New York; Chevy Chase, Md.; and Washington, D.C., is raising its biggest fund ever, shows a new SEC filing that shows target of $3.6 billion.

Alexandria RE Equities Launches ‘GradLabs’ Product in San Diego | GlobeSt

Office REIT Alexandria Real Estate Equities reports it has launched a new product geared to providing post-seed-stage life science companies with turnkey, fully furnished office/laboratory suites.

A $100 Genome Within Reach, Illumina CEO Asks If World Is Ready

Francis deSouza Photographer: Jeff Spicer/PA Wire via AP For years, the cost to decode a full human genome has been falling much like computer processing costs — from hundreds of thousands of dollars per person to about $1,000 today. With a $100 genome getting closer, the CEO of the top maker of DNA sequencers thinks the world may not be ready.

RFI Deadline Approaching: Understanding the Health of Women and the Role of Sex/Gender in Mechanisms of Heart, Lung, Blood, and Sleep Diseases and Disorders

The biomedical research community has made major progress in achieving a balance of men and women in human studies, however compelling questions about the underlying mechanisms that increase women’s risk or resilience for certain heart, lung, blood, and sleep (HLBS) diseases continue to challenge the scientific and medical community.

In support of its Strategic Vision, the National Heart, Lung, and Blood Institute (NHLBI) is advancing a scientific research agenda for women’s health. As part of that agenda, the Institute has issued a Request for Information “Understanding the Health of Women and the Role of Sex/Gender in Mechanisms of Heart, Lung, Blood, and Sleep Diseases and Disorders.” The RFI offers the research community, health care professionals, patient advocates, and others an opportunity to provide input on topics ranging from scientific gap areas in mechanisms of HLBS diseases, to training and resource needs, among other topics.

The NHLBI greatly values your perspective as it works with the wider scientific community to uncover the mechanisms of disease that will set a stronger foundation for clinical research focused on more effective prevention and treatment strategies for HLBS diseases and disorders in women. Please submit your responses via email to WHWGRFI@nhlbi.nih.gov by March 15, 2019. Don’t forget to include the Notice number (NOT-HL-18-660) in the subject line.

2018 was a record year for venture capital, but not for women founders – Washington Business Journal

The share of funding going to women-founded startups went down despite a massive influx of dollars to the region.

Pfizer: Countries free-riding on US innovation – BBC News

Albert Bourla told a US Senate hearing that other nations are “free-riding on American innovation”.

Sanofi, Bayer and Roche execs underscore the value of digital therapeutics – MedCity News

Biopharma companies have long been looking for a way to go beyond the molecule/pill.The nascent but growing digital therapeutics industry set to grow to $10 billion by 2023 may be guiding that way forward, according to a panel discussion on the second day of the DTx (Digital Therapeutics) West conference in San Mateo, California.

Van Hollen: Despite Trump, NIH Significantly ‘Better Off’ In Terms of Funding

Funding for the Bethesda-based National Institutes of Health is up by 14 percent during the two years that President Donald Trump has been in the White House — but it’s despite and not because of the president, according to Maryland Sen. Chris Van Hollen.

New Blood Test for 8 Common Cancers – Johns Hopkins Medicine

Johns Hopkins researchers have developed a unique, noninvasive blood test that detects proteins and gene mutations from eight common cancers. The test, called CancerSEEK, screens for cancers that account for more than 60 percent of U.S. cancer deaths.

This Viral Therapy Could Help Us Survive the Superbug Era

In November 2015, infectious disease epidemiologist Steffanie Strathdee and her husband, evolutionary psychologist Tom Patterson, were spending the week of Thanksgiving exploring pyramids and pharaoh’s tombs in Egypt when Patterson came down with what seemed like a nasty bout of food poisoning aboard their cruise ship. But as his condition rapidly deteriorated and he had to be emergency medevac’d, first to Germany and then to the medical center at UC San Diego, where both scientists were on staff, blood and imaging tests revealed why Patterson’s body was failing. A soccer-ball-sized cyst in his abdomen was infected—teeming with one of the most dangerous, antibiotic-resistant bacteria in the world.

Feb 28 2019

Love0

343rd Edition – February 26, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

February 26, 2019

FOUNDING MEMBER OF

2/28 SBIR & Non-Dilutive Funding Workshop

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW: https://tinyurl.com/BHISBIR2019

8:00 a.m. – Networking and Registration
8:30 a.m. – Welcome
8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute on Aging
- National Institute on Drug Abuse
- National Cancer Institute
9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab
10:00 a.m. – BREAK
10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation
11:00 a.m. – BREAK
11:15 a.m. – SBIR Funding Opportunities with USAMRC
11:45 a.m. – Lunch
12:45 p.m. – (1:1 Room Set)
1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)
2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
2:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously))
3:00 p.m. – 1:1 Meetings* (NIH only)
4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019No charge for entrepreneurs to attend • NOTE: Most 1:1 meeting(s) timeslots now are booked but when you list your agency interests in the RSVP we will be certain to let them know to follow up with you with more information.

FOURTH ANNUAL CRAB TRAP COMPETITION

YOU THOUGHT SHARK TANK WAS TOUGH?

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163

Submit your application for a chance to be named the Startup with the Most Commercial Potential at the BioHealth Capital Region Forum, win $10,000 and more!

APPLICATION DEADLINE: March 8, 2019

FINALISTS ANNOUNCED: March 21, 2019

PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Distinguished Judges:

Moderator – Rich Bendis, President and CEO, BioHealth Innovation

2019 Judges

John Rubin, Executive Director, JP Morgan Private Bank
Charles J. Andres, Intellectual Property Associate, Wilson Sonsini Goodrich & Rosati (WSGR)
Raghav Bhargava, Associate, New Enterprise Associates (NEA)
Ethel Rubin, NIH Entrepreneur in Residence
Shaun Grady, Vice-President Business Development Operations, AstraZeneca

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of attendees and prominent industry and venture capital judges

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

SAVE THE DATE – 2019 BioHealth Capital Region Forum

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

Register at bhcrf2019.eventbrite.com

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Danaher acquires GE Biopharma for $21.4B – Washington Business Journal

The deal is expected to close in the fourth quarter of this year.

BioHealth Innovation Entrepreneur-in-Residence Feedback – Feb. 27th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up by noon 3/26 to schedule your feedback session with BHI Entrepreneurs-in-Residence, who have industry experience in therapeutics, Dx, medtech and more, next Wednesday, February 27th. (Future sessions scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here (“EIR resource” at BHI). For questions/more information, contact BHI.

EXCLUSIVE: Amazon Real Estate Head Holly Sullivan Has No Regrets About The HQ2 Search

Amazon changed the rules of economic development when it announced a 50,000-job HQ2 sweepstakes in 2017. While most searches for large facilities happen behind closed doors, the Seattle tech giant kicked off an unprecedented, high-stakes, public battle for its next corporate home.

Maryland still outpacing California among best science, tech environments – Baltimore Business Journal

Maryland has the most computer and data scientists in the U.S., and the second-highest concentrations of engineers and life scientists.

RoosterBio Announces Plans to Expand Facility in Frederick, MD

RoosterBio, Inc, a privately held regenerative medicine manufacturing platform technology company announced plans today to expand the company’s footprint in Frederick, MD after a year of rapid growth.

Qiagen Gets Access to the Largest Genetic Database on Antibiotic Resistance

Under a new licensing deal, Qiagen will gain access to a big genetics database from Vienna-based Ares Genetics, which could help tackle the global health crisis of antibiotic resistance.

Microsoft, global health organizations launch 3 tech programs to catch rare diseases in children

Microsoft outlined how emerging technologies can support diagnosis of rare diseases among children in a report released Feb. 20.

Rare diseases affect almost 350 million people globally, and they can take an average of five years to diagnose, according to the report.

Antidote Therapeutics teams up with National Cancer Institute, seeks funding for nicotine-blocking drug candidate – Washington Business Journal

Matt Kalnik wants to make smoking less addictive.

His clinical-stage company, Gaithersburg-based Antidote Therapeutics Inc., is developing a drug that would diminish the effects of nicotine in the body — to both treat diseases worsened by nicotine and help smokers quit. The businesses is looking to raise between $5 million and $10 million to run over the next two years and get its lead candidate to clinical trials.

Maryland Momentum Fund accepting applications | Office of Technology Commercialization

The Maryland Momentum Fund is a newly-created mechanism for investing in promising early stage companies associated with the University System of Maryland (USM). Maryland-based companies that are seeking equity financing or debt financing that is convertible into equity may apply. The funding provided by the Fund will normally be in the range of $150K-$250K, with a ceiling of $500K. Recipients of this funding must obtain a matching investment (1:1) within six months, in either direction, from the date of commitment by the Fund.

TEDCO Creates Task Force to Support Women Entrepreneurs in Maryland

The Maryland Technology Development Corporation (TEDCO) announced today the formation of the Task Force for Women Entrepreneurs. The task force will be dedicated to the recruitment, funding, and operational support of women-owned and-led startups in Maryland.

University of Maryland Greenebaum Comprehensive Cancer Center Now Among Select Institutions Certified to Administer CAR T-cell Therapy for Lymphoma | UM Greenebaum Comprehensive Cancer Center

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is now certified to offer a groundbreaking treatment for non-Hodgkin lymphoma, in which a patient’s own immune cells are genetically engineered to recognize and attack the cancer.

Top 10 Immuno-Oncology Startups – GEN – Genetic Engineering and Biotechnology News

GlaxoSmithKline (GSK)’s recently announced $4.2 billion partnership to co-develop and co-commercialize Merck KGaA, Darmstadt’s cancer immunotherapy candidate M7824 was a reminder of just how much biopharma giants are willing to invest in a therapeutic area that has generated sometimes-dazzling results.

Kauffman Indicators of Entrepreneurship

The Kauffman Indicators of Entrepreneurship offers in-depth measures, reports, and accompanying interactive data visualizations that present entrepreneurial trends in the United States.

Like the rest of biopharma investors, corporate VCs love oncology | Evaluate

Novartis scatters its VC seeds widely by leading rounds across a variety of therapy areas, although oncology still represents a big share of its funding activity.

If We Don’t Develop Best Practices Ourselves, the Government Will

To spare you all a power point presentation, I thought I’d share some thoughts today about how and why our tech transfer system was created and the importance of practitioners continually developing best practices to maintain it.

Woody Allen said that half of life is showing up. Perhaps the other half is working with people who give you the opportunity to show what you can do.

MPM Capital raises $400M in seventh venture fund – MedCity News

A life sciences-focused venture capital firm based near Boston has raised more than one-third of a billion dollars to invest in early-stage companies.

Why Food Could Be the Best Medicine of All – Time

When Tom Shicowich’s toe started feeling numb in 2010, he brushed it off as a temporary ache. At the time, he didn’t have health insurance, so he put off going to the doctor. The toe became infected, and he got so sick that he stayed in bed for two days with what he assumed was the flu. When he finally saw a doctor, the physician immediately sent Shicowich to the emergency room. Several days later, surgeons amputated his toe, and he ended up spending a month in the hospital to recover.

Feb 28 2019

Love0

342nd Edition – February 20, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

February 20, 2019

FOUNDING MEMBER OF

Charles J. Andres, Associate, Intellectual Property with Wilson Sonsini, Goodrich & Rosati (WSGR), joins Rich Bendis for BioTalk to discuss his career, the opportunities/challenges in this industry, and WSGR’s role in the BioHealth Capital

Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.

Charlie has significant experience drafting patent applications, prosecuting patent applications in the U.S. and abroad, and evaluating the claims of issued patents. He has won cases before the Board of Patent Appeals and Interferences by brief and on oral argument. Patents Charlie has obtained have been listed in the Orange Book and asserted against a generic pharmaceutical manufacturer, and he has drafted and filed multiple applications for patent term extension. Companies he has obtained patents for have been sold for a cumulative total of approximately $4 billion.

Listen now on iTunes , Google Play , and TuneIn.

FOURTH ANNUAL CRAB TRAP COMPETITION

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163

Submit your application by March 1st for a chance to be named

‘the company with the most commercial potential’

at the BioHealth Capital Region Forum

Deadline for entries is March 1, 2019

Finalists will be announced March 21, 2019

Present at BioHealth Capital Region Forum April 9, 2019.

Finalists will have a chance to win the grand prize by presenting in front of a panel of world-class judges.

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of industry leaders and prominent industry funding experts and executives.

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

SAVE THE DATE – 2019 BioHealth Capital Region Forum

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

AstraZeneca retires MedImmune brand – Washington Business Journal

But not everything is expected to change at the Gaithersburg campus.

AURP’s Brian Darmody looks to make College Park office a hub for research parks – Technical.ly Baltimore

Among the organizations taking glass-enclosed office space in the recently opened WeWork at University of Maryland College Park is an organization looking to promote research parks that cluster minds in science and business.

Are the big corporate venture arms retreating? – Evaluate

At the beginning of this decade, when the fallout of the financial crash was still being felt and traditional venture firms were struggling to raise money, the investment arms of big pharma companies stepped in to fill a funding gap that was starving start-ups. Fast forward to the current period of plenty and, while corporate cash is no longer quite so crucial to the ecosystem, many of these units remain enthusiastic backers of early-stage science.

American Gene Technologies Signs Research Agreement with NIAID for Experimental HIV/AIDS Cure Strategy | American Gene Technology

American Gene Technologies (AGT) recently signed a Research Collaboration Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for research studies on AGT’s cell and gene therapy for HIV/AIDS. AGT uses its proprietary, genetically modified, autologous cell product (AGT103-T) to reconstitute the immune response against HIV with the goal of reducing persistent viral reservoirs and achieving sustained virologic remission in infected individuals in the absence of antiretroviral therapy. Under this collaboration agreement, NIAID researchers will study the mechanism of action for AGT103-T to define its potential impacts on HIV disease.

BioHealth Innovation Entrepreneur-in-Residence Feedback – Feb. 27th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up now to schedule your feedback session with BHI Entrepreneurs in Residence next Wednesday, February 27th. (Future sessions scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here (“EIR resource” at BHI). For questions/more information, contact BHI.

2-28 SBIR & Non-Dilutive Funding Workshop Agenda Set!

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW: https://tinyurl.com/BHISBIR2019

8:00 a.m. – Networking and Registration
8:30 a.m. – Welcome
8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute on Aging
- National Institute on Drug Abuse
- National Cancer Institute
9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab
10:00 a.m. – BREAK
10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation
11:00 a.m. – BREAK
11:15 a.m. – SBIR Funding Opportunities with USAMRC
11:45 a.m. – Lunch
12:45 p.m. – (1:1 Room Set)
1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)
2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
2:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously))
3:00 p.m. – 1:1 Meetings* (NIH only)
4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

Johns Hopkins Team to Commercialize Barrett’s Esophagus Epigenetic Biomarker Panel | GenomeWeb

A team of researchers led by the Johns Hopkins University of Medicine has developed a methylated epigenetic biomarker panel integrating a sponge-based collection tool and a methylated-bead PCR method that it believes can detect Barrett’s esophagus (BE).

Emergent BioSolutions (EBS) Appoints Seamus Mulligan to Board

Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan was a co-founder and principal investor of Adapt Pharma Ltd. and served as its chairman and CEO from 2014 until 2018, when Adapt was acquired by Emergent.

A $3.6 million grant will help UMD researchers advance cancer research – Arc Publishing

The National Institute of Health awarded a University of Maryland research center team of scientists $3.6 million to help fund their work on the cells responsible for destroying cancer cells.

QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens – MarketWatch

QIAGEN N.V. today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V. CURE, -0.10% to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing global health challenges posed by antibiotic-resistant bacteria.

Frederick-based Akonni Biosystems Awarded $3M NIH Phase 2 Award to Develop Low-Cost Tuberculosis Test

Akonni Biosystems, a molecular diagnostics (MDx) company that develops, manufactures, and intends to market advanced MDx systems, today announced receipt of a $3 million, three-year Phase II Small Business Innovation Research (SBIR) contract from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Akonni received the Phase I contract in August 2016.

Kousouris, Bailey Take New Leadership Roles at JHTV – JHTV

Steve Kousouris, who has been serving as Interim Executive Director of Technology Transfer at Johns Hopkins Technology Ventures since June, has assumed this role permanently effective Jan.1. Additionally, Mark Bailey, previously Associate Director of Finance, will assume responsibility for the portfolio that Steve has overseen since 2013 in the capacity of Director, Finance & Administration.

Kelly M. Schulz, State Secretary of Commerce – I95 Business

Kelly M. Schulz, the newly appointed state secretary of commerce, could be called the secretary of opportunity. Her vision for the state of Maryland is for economic development, job growth, full employment and economic prosperity for all families around the state.

Is that a robot? Dr. Bear Bot helps care for kids at local hospital. – The Washington Post

“How did you get in the robot?” That was the question a young patient at Children’s National Health System had on Thursday for Dr. Bear Bot.

18 charts to illustrate US VC in 2018 – PitchBook

Over the past couple of years, the term “record-breaking” has frequently been used to describe the state of venture capital in the US, as the space hits new heights with deal value, mega-rounds and fundraising. In 2018, some of these records reached heights not seen since the dot-com boom.

Pioneering Physician-Scientist to Receive 2019 Szent-Györgyi Prize for Progress in Cancer Research

The National Foundation for Cancer Research (NFCR) announced today that Steven A. Rosenberg, M.D., Ph.D., of the U.S. National Cancer Institute (NCI) has been selected to receive the 2019 Szent-Györgyi Prize for Progress in Cancer Research. The Prize selection committee awarded Dr. Rosenberg for not only revolutionizing—if not originating—the field now known as cancer immunotherapy but also remaining at its forefront. Chief of the NCI Center for Cancer Research’s surgery branch in Bethesda since 1974, his basic, translational and applied research efforts have contributed immeasurably to groundbreaking advances in therapy and the later development of drugs such as Chiron’s (later Novartis and Prometheus Labs’) Proleukin, Bristol-Myers Squibb’s Yervoy and Gilead’s Yescarta.

Unlucky 13: Top Clinical Trial Failures of 2018

Nuventra Pharma Sciences, a clinical pharmacology and PK/PD consultancy in Durham, NC, recently offered some insights on why clinical trials fail. In addition to biological considerations—such as pharmacokinetics, pharmacodynamic, and human response to a drug varying from animal models—Nuventra presented a list of reasons that included:

7 takeaways from HIMSS 2019 – MedCity News

Friday is the official last day of #HIMSS19 in Orlando. The annual healthcare conference, which began on Monday, February 11, was packed full of presentations, panels, products and people.

Novak Biddle from Roger Novak, Jack Biddle officially closes up shop – Washington Business Journal

The 22-year-old firm has invested in a number of well-known local companies.

Feb 28 2019

Love0

341st Edition – February 12, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

February 12, 2019

FOUNDING MEMBER OF

FOURTH ANNUAL CRAB TRAP COMPETITION

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163

Submit your application by March 1st for a chance to be named

‘the company with the most commercial potential’

at the BioHealth Capital Region Forum

Deadline for entries is March 1, 2019

Finalists will be announced March 21, 2019

Present at BioHealth Capital Region Forum April 9, 2019.

Finalists will have a chance to win the grand prize by presenting in front of a panel of world-class judges.

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of industry leaders and prominent industry funding experts and executives.

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

Startup CXO Database

Are you an experienced biohealth entrepreneur seeking new opportunities in the BioHealth Capital Region? BioHealth Innovation is developing a database of experienced industry personnel willing to work in potential C-suite positions with our university and startup partners. If you would like to have your contact information and vita included in this database for their review, please email BHI an updated vita by this Thursday, February 14th.

Brian Darmody Announced as AURP CEO & Launches ‘AURP HQ2’ in Washington, DC Area

The Association of University Research Parks (AURP), a professional association of university-related research and science parks, announced the appointment of Brian Darmody, Associate Vice President of Corporate Engagement at the University of Maryland (UMD), as its new Chief Executive Officer (CEO). Additionally, the association has opened a new office at the UMD Discovery District in the Washington, DC area, to be known as ‘AURP HQ2.’ Mr. Darmody will immediately assume his new role as CEO at the new location. He will continue his role at UMD and plans to transition out of UMD over time.

BioHealth Innovation Entrepreneur-in-Residence Feedback – Feb. 27th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan. Sign up now to schedule your feedback session with BHI EIRs on Wednesday, February 27th. (Next sessions scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here (“EIR resource”at BHI). For questions/more information, contact BHI.

2-28 SBIR & Non-Dilutive Funding Workshop Agenda Set!

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW: https://tinyurl.com/BHISBIR2019

8:00 a.m. – Networking and Registration
8:30 a.m. – Welcome
8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute on Aging
- National Institute on Drug Abuse
- National Cancer Institute
9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab
10:00 a.m. – BREAK
10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation
11:00 a.m. – BREAK
11:15 a.m. – SBIR Funding Opportunities with USAMRC
11:45 a.m. – Lunch
12:45 p.m. – (1:1 Room Set)
1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)
2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
2:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously))
3:00 p.m. – 1:1 Meetings* (NIH only)
4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

MacroGenics’ stock price more than doubles on successful breast cancer study – MedCity News

Shares of MacroGenics went stratospheric Wednesday following the release of data from a pivotal Phase III study of the company’s lead drug candidate in breast cancer that beat many investors’ expectations.

VLP Therapeutics to Initiate First Clinical Trial of VLPM01 Malaria Vaccine

VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company’s VLPM01 malaria vaccine. The Phase I/IIa clinical trial will begin recruiting participants in February 2019, and is designed to assess the safety, immunogenicity and efficacy of the VLPM01 vaccine. The clinical trial will be conducted at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, MD.

US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody (mAb) being developed for the prevention of lower respiratory tract infection (LRTI) caused by RSV.

The United States Of Venture Capital: The Most Active VC In Each State

Although startups based in California, New York, and Massachusetts have traditionally accounted for the majority of VC tech investment in the US, VCs are spurring other hotbeds of innovation across the country.

New Lab Space Designed to Attract Biotech Talent and Community Opens at 704 Quince Orchard – BioBuzz

When construction is completed this month, 704 QO will offer ready-to-occupy lab/office spaces for companies of all sizes. What really makes this new building stand out isn’t just the fully customizable individual lab units, but the suite of amenities that are tailored to the specific needs of emerging life science companies in the BioHealth Capital Region and the employees that work for them.

Look back at 10 of Baltimore tech’s biggest moments of the last decade – Technical.ly Baltimore

Today we’re celebrating around the Technical.ly Slack channel. It’s the 10th anniversary of Technical.ly’s founding in Philadelphia, marking a decade of local tech news and innovation community coverage.

PitchMasters™ hosts four emerging startups at January event, expands to Baltimore and New York – Shulman Rogers

PitchMasters™, a workshop-style event for entrepreneurs preparing for their first institutional capital raise, held its 2019 Kick Off and Alumni Event on Jan. 30, 2019. Four emerging startup companies, Skipiit, Trove Therapeutics, Uplift and VERALOX Therapeutics, practiced their pitching skills and gained insights from experienced entrepreneurs, investors, industry influencers and fellow PitchMasters™ alumni.

Growth In Life Sciences Innovation Triggers Demand For Real Estate Clusters

The life sciences industry is taking off, with the medical technology and biotech sectors expected to grow further as traditional pharmaceutical companies are joined by startups and incubator labs driving new research and development. And with life sciences innovation rising, so is demand for the space in which to innovate.

Beyond Wellness For the Healthy: Digital Health Consumer Adoption 2018 – Rock Health

Utilization of digital health services and technologies has been on the rise since we first began surveying the US adult population in 2015. Budding choices of wearables, apps, telemedicine, and other tech-enabled services make it easy for consumers to test out what it might be like to “go digital” for their health. In the first three years, our annual survey showed that tools for fitness and wellness represented a common (and low-risk) entry point for consumers to experiment with products that fit neatly into their already tech-enabled lifestyles. In the 2018 data that we examined for this report, we saw something different.

Feb 05 2019

Love0

340th Edition – February 5, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

February 5, 2019

FOUNDING MEMBER OF

FOURTH ANNUAL CRAB TRAP COMPETITION

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163

Submit your application for a chance to be named

‘the company with the most commercial potential’

at the BioHealth Capital Region Forum.

Deadline for entries is March 1, 2019

Finalists will be announced March 21, 2019

Present at BioHealth Capital Region Forum April 9, 2019.

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Moderator – Rich Bendis, President and CEO, BioHealth Innovation
2019 Judges to be announced

PRIZES

Grand Prize provided by WSGR $10,000
Visibility in front of hundreds of attendees and prominent industry and venture capital judges

CRITERIA

Product
Technical Feasibility
Marketing/Strategy
Leadership Team
Financial/Projection

Dr. Julia Finkel, Pediatric Anesthesiologist, Children’s National Medical Center, joins Biotalk host Rich Bendis

Dr. Julia Finkel, Pediatric Anesthesiologist, Children’s National Medical Center, joins Biotalk host Rich Bendis to discuss pain care management, the founding of startup AlgometRx, and the funding of this new companyDr. Julia Finkel, Pediatric Anesthesiologist, Children’s National Medical Center, joins Biotalk host Rich Bendis to discuss pain care management, the founding of startup AlgometRx, and the funding of this new company.

Julia Finkel, M.D., is a pediatric anesthesiologist and director Pain Medicine Research and Development in the Sheikh Zayed Institute for Pediatric Surgical Innovation.

Dr. Finkel has extensive experience designing and conducting clinical trials relating to analgesics in children and has received both industry and federal funding of her research. Dr. Finkel is regularly invited to speak at national meetings on topics related to pediatric pain management.

Listen now on iTunes , Google Play , and TuneIn.

SBIR & Non-Dilutive Funding Workshop – February 28th

UMD IBBR – 9600 Gudelsky Drive, Rockville, MD 20850

February 28, 2019

Unique opportunity to meet 1:1 with multiple SBIR program managers and experts.

SCHEDULE

8:00 a.m. – 8:30 a.m. – Networking and Registration
8:30 a.m. – 12:00 p.m. – Program Overviews. Agencies represented:
- NSF (National Science Foundation)
- NIH NIA (National Institute on Aging)
- NIH NCI (National Cancer Institute)
- NIH NHLBI (National Heart, Lung, and Blood Institute)
- NIH NIDA (National Institute on Drug Abuse)
- US Army (invited)
12:00 p.m. – 1:00 p.m. – Networking Lunch
1:00 p.m. – 1:30 p.m. – Writing Specific Aims Page
1:30 – 2 p.m. – Writing Your Phase II Commercialization Program
2:00 – 2:30 p.m. – Q&A with All speakers
2:30 – 4:00 p.m. – 1:1 – Meetings with Program Managers*

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019

No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

*You do not have to participate in 1:1 meetings. However, to do so, you must attend the overview session in person.

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management – Endpoints News

The partners at SR One, a storied corporate biotech VC with investments across a wide range of drug developers on both sides of the Atlantic, are engaged in talks to split away from the pharma giant GlaxoSmithKline, according to sources familiar with a move that’s been in the works since at least late last year.

Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced today that it has moved its U.S. Corporate Offices to 540 Gaither Road Suite 400 located in Rockville, Maryland. The company had previously been based in Baltimore, Maryland.

Montgomery County Economic Development Corporation Renews Support Commitment to Maryland Tech Council’s Venture Mentoring Services Program

Maryland Tech Council (MTC) announced today that the Montgomery County Economic Development Corporation (MCEDC) will continue its partnership with and support of MTC’s Venture Mentoring Services (VMS) program. MCEDC has funded the mentoring program for three years and will continue to support it in 2019-to further augment the growth of Montgomery County’s target industries-technology and life sciences, while providing a key component to sustain economic growth in the County.

GetWellNetwork poised to increase global footprint and drive digital health innovation across care continuum in 2019 | GetWellNetwork

GetWellNetwork, the Precision Engagement health care company reaching 10 million patients annually, announced today a pivotal 2018 which will propel the company into 2019 as it continues to lead the evolution of patient engagement. The company furthered global expansion efforts, made several executive hires and acquired leading digital health company HealthLoop to catalyze growth in the ambulatory space.

2018 Global Digital Health 100 – emocha included

Explore the 2018 Global Digital Health 100.

The Global Digital Health 100 is one of the HealthTech industries foremost technology awards programmes, celebrating innovation and entrepreneurship. It recognises and supports health technology companies that are demonstrating the greatest potential to change the way that healthcare is delivered.

Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types – Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/683,408, “Fluorocyclopentenylcytosine Methods of Use.” The patent application covers the use of RX-3117 in a broad range of tumor types that over-express UCK2, the enzyme that activates RX-3117. The company expects the patent to be issued within a few months from the notice of allowance and provide protection to 2036.

Viela Bio, NextCure among Maryland companies that received most VC funding in 2018. – Baltimore Business Journal

The top company received more than $280 million VC funding in 2018.

Billion-dollar year: Maryland builds venture capital momentum with record-breaking 2018 – Baltimore Business Journal

Seven firms brought in over $30 million last year, and five raised more than $70 million in venture capital.

Q4 2018 I-270 Lab Market Report

The extremely active lab real estate market is a bell-weather for the upcoming hyper-competitive talent market. Based on the recent real estate transactions and related hiring forecasts, we estimate the range of new positions in the Maryland life sciences market to be between 1,150 to 2,300 new hires in 2019.

Infographic: Visualizing the Future of the Pharma Market

By 2050, there will be two billion people that are 60 years or older globally. Meanwhile, the amount of seniors (65+ years old) in the U.S. will double to 100 million by 2060.

MdBio Foundation changes name to Learning Undefeated amid national expansion – Technical.ly Baltimore

In a move to reflect the reach into more states it has gained in recent years, MdBio Foundation unveiled a rebrand as Learning Undefeated on Tuesday.

FITCI is a incubator and accelerator for science and technology-based business.

Community members gathered Wednesday night at Hood College’s Hodson Auditorium to celebrate Frederick Innovative Technology Center Inc.’s 15th anniversary.

VitusVet, eying growth, hires OrderUp cofounder as COO – Technical.ly Baltimore

Like a lot of medical practices, veterinarians seek to send patients a message when they’re due for a check-up, schedule appointments and keep track of medical records. Yet Marc Olcott sees a lot of those tasks still happening by phone or on paper, and thinks it should all be available digitally.

Here are this year’s 20 most promising startups in Baltimore: realLIST 2019 – Technical.ly Baltimore

For the people looking to move within a thriving tech community, it’s important to be able to easily call upon the key players.

Equity Crowdfunding for Biotech Startups: Does it Work?

In the last decade, crowdfunding has become a popular way to finance all sorts of projects and products. Biotech is no exception, but many question whether the high risk and long term nature of investing in the biotech industry makes it a good fit for equity crowdfunding.

Keiretsu Forum Mid-Atlantic Partners and CONNECTpreneur to Advance Innovation and Entrepreneurship – Press Release – Digital Journal

The premier investor network in the Mid-Atlantic has entered into a resource partnership. Keiretsu Forum Mid-Atlantic and the CONNECTpreneur community have entered into an agreement that will advance innovation, entrepreneurship, and investment in the region.

Lung Cancer May Be Sniffed Out Earlier with Graphene e-Nose

Lung cancer may not be the first thought that crosses the mind when talking about breathalyzer tests. But, what if lung cancer detection were as easy as breathing into a device? That is the goal of a group of researchers from the University of Exeter who have recently taken a new approach to e-nose technology integrated with multi-layered graphene for early detection of lung cancer.

Accelerating Swiss innovations to market with strategic collaboration

Catalyze announces collaboration with Biopôle, providing dedicated services to members towards better access to non-dilutive funding opportunities.

Feb 05 2019

Love0

339th Edition – January 29, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

January 29, 2019

FOUNDING MEMBER OF

Win $ and Visibility in Front of Hundreds of Attendees at the 2019 BHCR Crab Trap

You thought the Shark Tank was tough…Wait until you enter the the BioHealth Capital Region Crab Trap!

Submit your application for the opportunity to present your innovation and be named the region’s early stage biohealth company with the most commercial potential at the 2019 BioHealth Regional Forum, $10,000, and MORE!

Application Deadline: March 1, 2019

Finalists will be announced: March 21st, 2019

Finalist Presentations BioHealth Capital Region Forum event: April 9th, 2019

Submit Application »

MaxCyte: Driving New Generation of Cell-Based Medicines – WXPress – Global open-access R&D enabling platform, life science industry news and perspectives

Cell therapy offers a treasure chest of new medicines, but there is still much to learn about cell activities and how to deliver these potential benefits before science and the industry can fully fulfill on their promise. One of cell therapy’s earliest pioneering companies is MaxCyte, based in Gaithersburg, MD and in the United Kingdom. Leading MaxCyte is president and CEO Doug Doerfler, a biotech pioneer who has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was also a founder of MaxCyte in July 1998.

Emocha wants to help Type 2 diabetes patients stick to their drug regimens

This new program is specifically aimed at helping patients with Type 2 diabetes, who take medications to control their blood sugar levels.

United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag

United Therapeutics Corporation (Nasdaq: UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). Under the agreement, United Therapeutics acquired exclusive, worldwide rights to develop and manufacture the Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Upon closing, United Therapeutics paid Arena $800 million. Arena is also entitled to potential milestone payments of up to $400 million based on the achievement of certain regulatory events as well as low double-digit tiered royalties on annual net sales of ralinepag products.

SBIR and Other Non-Dilutive Funding Sources – February 28

HOLD THE DATE – February 28, 2019 8 am. – 3:00 p.m.

Meet 1:1 with SBIR program managers. Learn more about their funding programs (SBIR and more!)

8-8:30 Networking and Registration

8:30 – 12:00 p.m. – Program Overviews

12:00 p.m. – 1:00 p.m. – Networking Lunch

1:00 p.m. – 3:00 p.m – 1:1 Meetings with Program Managers*

Agencies represented include: NSF, NIH NIA, NIH NCI, NIH NHLBI, NIH NIDA, US Army (invited)

*The program overview will be available by videoconference.

**You do not have to participate in 1:1 meetings. However, to do so, you must attend the overview session in person.PRE-REGISTRATION IS REQUIRED: RSVP by noon 2/26: BHI@BioHealthInnovation.org

Well Doc’s BlueStar highlighted on Forbes’ list of Digital Healthcare Growth Drivers

The digital transformation of healthcare will see significant growth in the next 12 months fueled by institutional interest in driving down costs and improving patient engagement. Expect increased pharma investment, improving regulatory status, payer engagement with digital tools and better telemedicine connectivity through consolidation.

Maryland E-Nnovation initiative provides matching funds for tech-focused research endowments – Technical.ly Baltimore

Four Maryland colleges are expanding tech-focused programming with funding from a state program.

The Maryland E-Nnovation Initiative Fund was created to spur research in scientific and technical fields at colleges and universities in the state.

Report: Most investment in DC-area cybersecurity startups goes to Maryland, Virginia – Technical.ly DC

Washington, D.C.–based cybersecurity investment firm Strategic Cyber Ventures released its first annual report on The State of 2018 Cybersecurity Investing that includes some key findings about the DMV.

GCTCI: Washington DC ranked as the top city globally for talent competitiveness

Washington, D.C. has been crowned as the city that’s leading the way in talent competitiveness, thanks to its ability to attract and nurture entrepreneurs, whilst meeting the needs of being a strongly-connected, “global” city.

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management – Endpoints News

Education Top Budget Priority For Maryland With Record Funding For 2020 – CBS Baltimore

Gov. Hogan’s new fiscal 2020 budget is officially on the table, and it’s getting a preliminary thumbs up from the Democratic leadership in the General Assembly.

This year’s budget may go above and beyond when it comes to kids.

gel-e Expands Patent Estate with Next Level of Exclusivity

gel-e Inc., announces the issuance of United States Patent Number 10,179,145 by the U.S. Patent and Trademark Office, which broadly claims and discloses uses of the Company’s core technology.

Over-regulating drugs threatens Md. Life sciences industry – Baltimore Sun

One major focus for legislators during this year’s session is how to bring down the cost of health care, as everyday Marylanders struggle to afford the cost they pay at the pharmacy counter. Despite disagreements between different groups within and beyond health care, there is broad consensus that something must be done about the cost patients pay without denying Marylanders the world-class treatments available to them, many of which are made right here in Maryland.

Demystifying industry–academia collaboration

The past decade has seen intensified research collaboration between pharmaceutical companies and academic institutions. Although such partnerships are recognized as a source of innovation and a key pillar to advance science in drug discovery, they are replete with challenges. Despite much anecdotal evidence and debate, fact-based evidence on the nature of these challenges and how to manage them is scarce.

The State of Health Care Innovation in 2019: The World Awaits – LinkedIn

2019 has kicked off with a wave of innovative health care solutions highlighted at mega-conferences like CES and the J.P. Morgan Healthcare Conference – from the introduction of the first wearable blood pressure monitor to virtual home health care for seniors to online vision tests allowing patients to renew prescriptions from anywhere at anytime. We are truly living through an age of disruption spurred by technological advances.

10 Takeover Targets to Watch in 2019

After weeks of speculation that biopharma deal making would cool off, 2019 got off to a flying start as far as mergers-and-acquisitions (M&A) is concerned, thanks to two blockbuster transactions: Bristol-Myers Squibb’s planned $74 billion acquisition of Celgene, followed four days later by Eli Lilly’s planned $8 billion purchase of Loxo Oncology—a deal that quickly became the buzz of the J.P. Morgan 37th Healthcare Conference, held earlier this month in San Francisco.

Spring 2019 NCI-UMD Partnership for Integrative Cancer Research Symposium

Our National Cancer Institute-University of Maryland (NCI-UMD) Partnership for Integrative Cancer Research reflects the broad interests of our participating NCI and UMD researchers. We are delighted to invite you to our annual NCI-UMD Partnership for Integrative Cancer Research Symposium on Friday, February 8th from 10am-4pm which will take place in Bethesda, Maryland in the John Edward Porter Neuroscience Research Center at the National Institutes of Health, Bldg 35A, Room 620/630. Please register and plan to participate in our October symposium. The final agenda will be announced shortly.

Jonathan Aberman: Why are we using Silicon Valley’s entrepreneurship model? – Washington Business Journal

We need to chart a new course.

Diet, the Gut Microbiome, and Colorectal Cancer: Are They Linked?

Colorectal cancer (CRC) is one of the leading causes of death in the western society, being ranked third most lethal neoplasia in the United States in both men and women.1 In 2014, the American Cancer Society estimated that approximately 136,830 new cases of CRC will be diagnosed in the United States, with more than 50,000 Americans expected to die due to disease progression or complications.1,2 The lifetime cancer-related costs are considerable and differ by cancer site, disease stage, age at diagnosis, and treatment phase. Considering direct healthcare costs, CRC is the second most important neoplasia with estimated expenses of more than $14 billion.3,4

Deloitte named world’s most valuable professional services brand | Deloitte China | Newsroom

Deloitte has surpassed its peers to become the world’s most valuable professional services brand, according to the 2019 Global 500 report issued by Brand Finance on 22 January 2019. Deloitte’s strong performance was due to higher scores in Brand Finance’s metrics of familiarity, consideration, satisfaction, preference, recommendation and revenue.

First CRISPR Clinical Trial Begins in Europe | Scienceline

The highly touted gene-editing technology CRISPR is facing one of its first real-world tests. As many as 12 patients who live with the blood disorders sickle cell anemia or beta-thalassemia have started enrolling in a Europe-based clinical trial that may serve as an early indicator of whether gene editing will live up to the hype.

BHI Weekly Newsletter Archives

About BioHealth Innovation

Contact

Connect